Cell cycle progression is promoted by CDK6 through interaction with D-type cyclins to phosphorylate the retinoblastoma tumor suppressor and displays oncogenic potency by kinase activity in several types of malignant tumors (6–8). Here, CDK6 is linked to cancer.